Clearway Energy is rated as a 'Buy' due to its stable cash flow, strong growth prospects, and ability to reprice power generation assets to increase returns. The company expects contract repricing and repowering initiatives to drive growth in cash available for distribution (CAFD), aiming for $2.70 per share in 2027, up from $2.12 in 2025. Trading at $29.93 per share with an 11.1x 2027 CAFD multiple, Clearway offers potential total returns of 15–24%, supported by dividends and price appreciation. Key risks include variability in renewable resources, project delays, equity dilution, and execution challenges on projects and financing.
Clearway Energy's cash flow and contract upgrade prospects provide context for this snapshot of the Energy sector on Pluang as of Oct 20, 2026 04:41 WIB: Among 79 priced US energy stocks, 29 rose and 49 fell. Valaris Limited Common Shares (VAL) led gains with a 5.08% increase to USD 89.65 and a typical hold time of 5 days, while Transocean Ltd (RIG) rose 5.07% to USD 5.91 with 100% buy orders and a typical hold time of 18 days. Sunrun Inc (RUN) declined 5.21% to USD 6.92 despite 100% buy orders and a 17-day hold time.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
